WVE · XBRL financial data

Wave Life Sciences financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (WVE's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	20	41	4	113	108	43
Research and development	131	122	116	130	160	183
General and administrative	43	46	51	51	59	75
Total operating expenses	173	168	166	181	219	258
Operating income (loss)	(153)	(127)	(163)	(68)	(110)	(215)
Other income (expense)	2	5	0	2	3	1
Income tax expense (benefit)	(1)	(0)	1	(1)	0	0
Net income (loss)	(150)	(122)	(162)	(58)	(97)	(204)
Earnings per share, basic USD per share	—	(2.36)	(2.05)	(0.54)	(0.70)	(1.21)
Earnings per share, diluted USD per share	—	(2.36)	(2.05)	(0.54)	(0.70)	(1.21)
Weighted average shares, basic millions of shares	—	52	79	106	138	169
Weighted average shares, diluted millions of shares	—	52	79	106	138	169

Fiscal years (WVE's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	184	151	88	200	302	602
Marketable securities	—	—	—	—	—	0
Marketable securities, non-current	—	—	—	—	—	0
Accounts receivable	30	—	—	21	1	1
Total current assets	230	163	99	235	320	615
Property and equipment, net	29	22	17	13	10	7
Right-of-use asset	16	18	27	23	18	12
Total assets	279	207	146	275	352	638
Accounts payable	14	7	17	13	16	16
Accrued liabilities	2	4	4	2	5	7
Total current liabilities	121	64	72	186	111	95
Lease liability, non-current	26	25	32	25	18	9
Total liabilities	189	167	184	227	135	112
Accumulated deficit	(683)	(806)	(967)	(1,025)	(1,122)	(1,326)
Total stockholders' equity	83	32	(45)	40	210	518
Total liabilities and equity	279	207	146	275	352	638
Common shares outstanding (cover page) millions of shares	49	61	98	122	153	188

Fiscal years (WVE's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(150)	(122)	(162)	(58)	(97)	(204)
Net cash from operating activities	(116)	(89)	(128)	(19)	(151)	(187)
Purchases of property and equipment	1	1	1	1	1	1
Net cash from investing activities	(1)	(1)	(1)	(1)	(1)	(1)
Proceeds from issuing common stock	94	—	51	94	—	—
Net cash from financing activities	155	56	67	133	254	488
Net change in cash	37	(34)	(62)	112	102	300

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Wave Life Sciences	197	13	(60)*	197.2M	7.4 quarters	Q3 FY26 10-QSep 30, 2026
Geron	69	60	10*	644.2M	—	Q3 FY26 10-QSep 30, 2026
Intellia Therapeutics	106	7.7	(83)*	140.1M	5.3 quarters	Q2 FY26 10-QJun 30, 2026
Niagen Bioscience	70	27	2.6*	79.2M	—	Q3 FY26 10-QSep 30, 2026
Nurix Therapeutics	720	673	616*	109.2M	—	Q3 FY26 10-QAug 31, 2026
Syndax Pharmaceuticals	136	83	(27)*	not reported	11.9 quarters	Q3 FY26 10-QSep 30, 2026
CorMedix	257	102	86*	77.9M	—	Q2 FY26 10-QJun 30, 2026
Merus	367	12	(85)*	75.8M	7.5 quarters	Q3 FY25 10-QSep 30, 2025
Ardelyx	46	128	2.2*	251.4M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.